Symbolbild · KI-generiert
NurExone Biologic Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
NurExone is a TSX Venture Exchange (' TSXV '), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company's roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top to anchor its North American activity and growth strategy.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| NurExone Biologic Inc. | NRX | TSXV | 30 Mio. USD |
| BriaCell Therapeutics Corp. | BCT | TSX | 30 Mio. USD |
| Sernova Biotherapeutics Inc. | SVA | TSX | 30 Mio. USD |
| Microbix Biosystems Inc. | MBX | TSX | 29 Mio. USD |
| Rockwell Medical Inc. | RMTI | NASDAQ | 28 Mio. USD |
| Perimeter Medical Imaging AI Inc. | PINK | TSXV | 32 Mio. USD |
| MedMira Inc. | MIR | TSXV | 32 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.